Noncoding RNA in drug resistant sarcoma

15Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant development of multidisciplinary treatments for sarcoma, survival rates have reached a plateau. Chemotherapy has been extensively used for sarcoma treatment; however, the development of drug resistance is a major obstacle limiting the success of many anticancer agents. Sarcoma biology has traditionally focused on genomic and epigenomic deregulation of protein-coding genes to identify the therapeutic potential for reversing drug resistance. New and more creative approaches have found the involvement of noncoding RNAs, including microRNAs and long noncoding RNAs in drug resistant sarcoma. In this review, we discuss the current knowledge of noncoding RNAs characteristics and the regulated genes involved in drug resistant sarcoma, and focus on their therapeutic potential in the future.

Cite

CITATION STYLE

APA

Li, X., Shen, J. K., Hornicek, F. J., Xiao, T., & Duan, Z. (2017, July 6). Noncoding RNA in drug resistant sarcoma. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.19029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free